(28) reported the case of a 68-year-old man affected by metastatic mesothelioma who presented with polydipsia and polyuria after the third cycle of a combination treatment of tremelimumab (an anti-CTLA4 mAb; 1 mg/Kg iv every four weeks for four cycles) and durvalumab (an anti-PD-L1 mAb; 20 mg/Kg iv every four weeks). The gene discussed is CD274; the disease is Polydipsia.